Condition: Solid Tumor, Unspecified, Adult · Haematological Malignancy · Sponsor: Morten Ladekarl
Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region. Treatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.
This description comes directly from the study's public registry record.
Morten Ladekarl, MD, DMSci · +45 97660545 · morten.ladekarl@rn.dk
Anja Pagh, MD, PhD · +45 97661417 · a.pagh@rn.dk
Always discuss trial participation with your own doctor first.
| Department of Oncology, Aalborg University Hospital | Aalborg, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05695638